Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis

Cell Death and Differentiation

Volumn 19, Issue 7, 2012, Pages 1220-1227

  Gramling, M W ^a   Eischen, C M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Erk; Ksr; lymphoma; Myc; p53; Ras

Indexed keywords

KSR1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN; PROTEIN P53; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; GENE DELETION; GENE OVEREXPRESSION; LYMPHOMA; LYMPHOMAGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NIH 3T3 CELLS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

MUS; MUS MUSCULUS;

EID: 84862152148     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2012.1     Document Type: Article

References (40)

1. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533-538.
2. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARFMdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13: 2658-2669.
3. Watanabe T, Ichikawa A, Saito H, Hotta T. Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymphoma 1996; 21: 391-397.
4. Young KH, Leroy K, Moller MB, Colleoni GW, Sanchez-Beato M, Kerbauy FR et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008; 112: 3088-3098.
5. Moller MB, Ino Y, Gerdes AM, Skjodt K, Louis DN, Pedersen NT. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia 1999; 13: 453-459.
6. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007; 26: 3113-3121.
7. Claperon A, Therrien M. KSR and CNK: two scaffolds regulating RAS-mediated RAF activation. Oncogene 2007; 26: 3143-3158.
8. Nguyen A, Burack WR, Stock JL, Kortum R, Chaika OV, Afkarian M et al. Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo. Mol Cell Biol 2002; 22: 3035-3045.
9. Denouel-Galy A, Douville EM, Warne PH, Papin C, Laugier D, Calothy G et al. Murine Ksr interacts with MEK and inhibits Ras-induced transformation. Curr Biol 1998; 8: 46-55.
10. Kortum RL, Johnson HJ, Costanzo DL, Volle DJ, Razidlo GL, Fusello AM et al. The molecular scaffold kinase suppressor of Ras 1 is a modifier of RasV12-induced and replicative senescence. Mol Cell Biol 2006; 26: 2202-2214.
11. Lozano J, Xing R, Cai Z, Jensen HL, Trempus C, Mark W et al. Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice. Cancer Res 2003; 63: 4232-4238.
12. Razidlo GL, Kortum RL, Haferbier JL, Lewis RE. Phosphorylation regulates KSR1 stability, ERK activation, and cell proliferation. J Biol Chem 2004; 279: 47808-47814.
13. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, Talpaz M, Cork A, Freireich EJ et al. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangementnegative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 1990; 76: 1214-1219.
14. Case M, Matheson E, Minto L, Hassan R, Harrison CJ, Bown N et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res 2008; 68: 6803-6809.
15. Kiessling MK, Oberholzer PA, Mondal C, Karpova MB, Zipser MC, Lin WM et al. Highthroughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood 2011; 117: 2433-2440.
16. Alexander WS, Bernard O, Cory S, Adams JM. Lymphomagenesis in E mu-myc transgenic mice can involve ras mutations. Oncogene 1989; 4: 575-581.
17. Schwartz RC, Stanton LW, Riley SC, Marcu KB, Witte ON. Synergism of v-myc and v-Haras in the in vitro neoplastic progression of murine lymphoid cells. Mol Cell Biol 1986; 6: 3221-3231.
18. Langdon WY, Harris AW, Cory S. Acceleration of B-lymphoid tumorigenesis in E mu-myc transgenic mice by v-H-ras and v-raf but not v-abl. Oncogene Res 1989; 4: 253-258.
19. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM et al. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455: 679-683.
20. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 1995; 23: 1686-1690.
21. Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell 1999; 3: 169-179.
22. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17: 5001-5014.
23. Alt JR, Greiner TC, Cleveland JL, Eischen CM. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J 2003; 22: 1442-1450.
24. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011; 471: 235-239.
25. Green MR, Aya-Bonilla C, Gandhi MK, Lea RA, Wellwood J, Wood P et al. Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma. Genes Chromosomes Cancer 2011; 50: 313-326.
26. Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL. Bax loss impairs myc-induced apoptosis and circumvents the selection of p53 mutations during myc-mediated lymphomagenesis. Mol Cell Biol 2001; 21: 7653-7662.
27. Wang P, Lushnikova T, Odvody J, Greiner TC, Jones SN, Eischen CM. Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells. Oncogene 2008; 27: 1590-1598.
28. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348: 331-333.
29. Xiao H, Zhang Q, Shen J, Bindokas V, Xing HR. Pharmacologic inactivation of kinase suppressor of Ras1 sensitizes epidermal growth factor receptor and oncogenic Ras-dependent tumors to ionizing radiation treatment. Mol Cancer Ther 2010; 9: 2724-2736.
30. Kim M, Yan Y, Kortum RL, Stoeger SM, Sgagias MK, Lee K et al. Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity. Cancer Res 2005; 65: 3986-3992.
31. Eischen CM, Packham G, Nip J, Fee BE, Hiebert SW, Zambetti GP et al. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene 2001; 20: 6983-6993.
32. Eischen CM, Woo D, Roussel MF, Cleveland JL. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol 2001; 21: 5063-5070.
33. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 2004; 101: 6164-6169.
34. Felsher DW. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res 2008; 68: 3081-3086; discussion 3086.
35. Tran PT, Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J et al. Combined inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One 2008; 3: e2125.
36. Xing HR, Cordon-Cardo C, Deng X, Tong W, Campodonico L, Fuks Z et al. Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Nat Med 2003; 9: 1266-1268.
37. Llobet D, Eritja N, Domingo M, Bergada L, Mirantes C, Santacana M et al. KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels. Am J Pathol 2011; 178: 1529-1543.
38. Scholl FA, Dumesic PA, Barragan DI, Harada K, Charron J, Khavari PA. Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia. Cancer Res 2009; 69: 3772-3778.
39. Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 2009; 16: 324-335.
40. Bhalla S, Evens AM, Dai B, Prachand S, Gordon LI, Gartenhaus RB. The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. Blood 2011; 118: 1052-1061.